98%
921
2 minutes
20
Amphetamine abuse is a major public health concern for which there is currently no effective treatment. To develop effective treatments, the mechanisms by which amphetamine produces its abuse-related effects need to be fully understood. It is well known that amphetamine exerts its actions by targeting high-affinity transporters for monoamines, in particular the cocaine-sensitive dopamine transporter. Organic cation transporter 3 (OCT3) has recently been found to play an important role in regulating monoamine signaling. However, whether OCT3 contributes to the actions of amphetamine is unclear. We found that OCT3 is expressed in dopamine neurons. Then, applying a combination of in vivo, ex vivo, and in vitro approaches, we revealed that a substantial component of amphetamine's actions is OCT3-dependent and cocaine insensitive. Our findings support OCT3 as a new player in the actions of amphetamine and encourage investigation of this transporter as a potential new target for the treatment of psychostimulant abuse.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180071 | PMC |
http://dx.doi.org/10.1038/s41386-018-0053-5 | DOI Listing |
European J Org Chem
September 2024
Department of Chemistry, Vanderbilt University, Nashville, TN-37235.
The iboga alkaloids are a family of monoterpene indole alkaloids first discovered from the root of . The major alkaloid constituent in the root, ibogaine, has garnered interest for its anti-addictive properties. Ibogaine has been shown to reduce opiate, amphetamine, alcohol, and nicotine self-administration in rodents.
View Article and Find Full Text PDFPLoS One
August 2025
Institute of Neuroscience, University of Oregon, Eugene, Oregon, United States of America.
Psychedelics show promise in treating depression, PTSD, and substance use disorder, prompting research into their mechanisms of action. Most studies use rodent models, but genetic tools can be challenging to apply in this approach. Invertebrate models, like C.
View Article and Find Full Text PDFMethodist Debakey Cardiovasc J
August 2025
Emeritus Executive Director of Academic Affairs, Cleveland Clinic and Emeritus Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio US.
This edition of Poet's Pen focuses on a rare but catastrophic complication associated with methamphetamine, the use of which is progressively rising in certain parts of the country. The featured poem, "The Pulse of a Silent Killer," shows the utility of poetry to sound the alarm amidst an emergency, alerting the medical community that all may not be as it seems. According to its author, the piece "reflects the rising crisis of methamphetamine-induced cardiomyopathy among young adults in Texas.
View Article and Find Full Text PDFNervenarzt
September 2025
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Fakultät Dresden, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.
Methamphetamine (MA) is one of the most relevant illegal drugs of our time worldwide. In German hospitals the management of a variety of MA-associated problems are also part of the daily routine, especially in the central area of Germany. A rapid infiltration of the central nervous system, pronounced dopaminergic stimulation and a long-term effect together with easy availability are the reasons for the enormous potential for dependency.
View Article and Find Full Text PDFJ Clin Psychiatry
July 2025
Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas.
This study evaluated whether depressive symptom severity improved early with extended-release naltrexone and bupropion combination (naltrexone bupropion) compared to a placebo in individuals with moderate/severe methamphetamine use disorder and predicted subsequent use of methamphetamine. This secondary analysis from the Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT-2) trial, which was conducted from May 23, 2017-July 25, 2019, included 326 individuals with a 9-item Patient Health Questionnaire (PHQ-9) score ≥5 at baseline. Repeated-measures mixed model analyses evaluated early (baseline-to-week-4) changes in depressive symptom severity with naltrexone-bupropion versus placebo and provided slope estimates for PHQ-9 change.
View Article and Find Full Text PDF